

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)



(10) International Publication Number
WO 2025/179091 A2

(51) International Patent Classification:

A61K 9/20 (2006.01) C07D 311/00 (2006.01)
A61K 31/381 (2006.01) A61K 9/14 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2025/016707

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(22) International Filing Date:

21 February 2025 (21.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/557,163 23 February 2024 (23.02.2024) US

(71) Applicant: SUMITOMO PHARMA AMERICA, INC.

[US/US]; 84 Waterford Drive, Marlborough, Massachusetts
01752 (US).

(72) Inventors: CHEN, Xiaoxia; c/o Sumitomo Pharma Amer-

ica, Inc., 84 Waterford Drive, Marlborough, Massachusetts
01752 (US). JAMZAD, Shahla; c/o Sumitomo Pharma
America, Inc., 84 Waterford Drive, Marlborough, Massa-
chusetts 01752 (US). SNOONIAN, John; c/o Sumitomo
Pharma America, Inc., 84 Waterford Drive, Marlborough,
Massachusetts 01752 (US). ZAMAN, Noreen; c/o Sumit-
omo Pharma America, Inc., 84 Waterford Drive, Marlbor-
ough, Massachusetts 01752 (US). ZHANG, Haitao; c/o Su-
mitomo Pharma America, Inc., 84 Waterford Drive, Marl-
borough, Massachusetts 01752 (US).

(74) Agent: FREDERICKS, Kellie; Heslin Rothenberg Farley

& Mesiti P.C., 5 Columbia Circle, Albany, 12203 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ULOTARONT HYDROCHLORIDE MANUFACTURING PROCESS

(57) Abstract: This disclosure provides improved methods of manufacturing ulotaront HCl, for reducing impurities in ulotaront HCl, and for processing ulotaront HCl into finished dosage forms.

WO 2025/179091 A2